BiotechTube

GLIADEL

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Brain Cancer

Conditions

Metastatic Brain Cancer

Trial Timeline

Dec 12, 2007 → Dec 1, 2010

NCT ID
NCT00525590

About GLIADEL

GLIADEL is a phase 2 stage product being developed by Eisai for Metastatic Brain Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00525590. Target conditions include Metastatic Brain Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Metastatic Brain Cancer were approved

Approved (20) Terminated (8) Active (0)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enfortumab VedotinAstellas PharmaApproved
✅EligardAstellas PharmaApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00525590Phase 2Completed

Competing Products

20 competing products in Metastatic Brain Cancer

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
11
AbemaciclibEli LillyPre-clinical
26
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
44
SYNB1891 + AtezolizumabSynlogicPhase 1
11
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
40
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
32
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
Induction therapyChugai PharmaceuticalPhase 2
42
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
35
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
35
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
31
GC33Chugai PharmaceuticalPhase 1
29
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
44